- Mink Therapeutics Principal Financial Officer Melissa Orilall filed an initial Form 3.
- Filing reported 222 shares of common stock held indirectly by spouse as of March 13, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-149642), on April 09, 2026, and is solely responsible for the information contained therein.
Comments